Oncimmune: Platform biomarker company with proprietary EarlyCDT® technology. Developing and commercialising autoantibody (AAb) tests that can enable detection 4 years or more before standard clinical diagnosis, and stratify patients into response to treatment. Two marketed products, EarlyCDT®-Lung launched in 2012 and EarlyCDT®-Liver launched in 2018, and a broad advanced pipeline of early cancer detection tests, incl. prostate, breast and ovarian. Global presence, incl. US (155m US lives covered; 156,000 EarlyCDT®-Lung tests sold since launch) and China. Leading immunogenic library; broad and comprehensive patent portfolio.
184 Shepherd’s Bush Road
London, W6
United Kingdom

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.